SCOTTSDALE, ARIZONA
Alternative Pancreatic Cancer Treatment & Integrative Pancreatic Cancer Care in Scottsdale, Arizona
A More Individualized Approach to Pancreatic Cancer Treatment
Few diagnoses create the same sense of urgency as pancreatic cancer.
Within days, patients and families may be trying to understand CT scans, pathology reports, CA 19-9 levels, surgery, chemotherapy, radiation, genetic testing and unfamiliar terms such as resectable, borderline resectable, locally advanced and metastatic disease.
And almost immediately, another question often arises:
Are there additional treatment options—and is there anything more that can be done to support the patient while the cancer is being treated?
At Sunridge Medical in Scottsdale, Arizona, we see patients at many different points in the pancreatic-cancer journey: newly diagnosed patients seeking another perspective, people undergoing conventional treatment who want a more comprehensive approach, patients dealing with difficult treatment-related symptoms, and patients with advanced or metastatic disease who want to understand what options may still remain.
Our philosophy is straightforward:
Pancreatic cancer treatment should begin with understanding the individual patient—not simply applying the same protocol to everyone with the same diagnosis.
An individualized evaluation can consider the exact pathology, location and extent of disease, whether surgery may be possible, previous treatments, molecular and genetic findings, current medications, laboratory results, nutritional status, treatment tolerance, other medical conditions and the patient’s goals.
The objective is not to choose between “conventional” and “alternative” medicine as though they are opposing philosophies.
The objective is to determine what is medically appropriate, what is supported by evidence, what may help the patient tolerate treatment and what options deserve further consideration in that individual case.
What Does “Alternative Pancreatic Cancer Treatment” Actually Mean?
People searching for alternative pancreatic cancer treatment are not necessarily looking for the same thing.
Some want to avoid chemotherapy. Some are already receiving chemotherapy and want additional support. Some have been told that their cancer is not operable. Others have experienced cancer progression and are searching for options after one or more treatments have stopped working. Still others simply want another physician to look at the entire picture.
The terminology matters.
Complementary cancer care generally describes therapies used alongside conventional cancer treatment.
Alternative treatment typically means using a treatment in place of conventional therapy.
Integrative oncology combines conventional cancer treatment with evidence-informed complementary approaches while taking the patient’s overall health, symptoms, preferences and treatment goals into account.1
At Sunridge Medical, our approach is individualized rather than ideological.
We do not believe that a treatment becomes effective simply because it is described as “natural.” We also do not believe that every potentially useful supportive or integrative approach should automatically be dismissed because it falls outside routine oncology.
The evidence, the patient and the clinical situation all matter.
Why Pancreatic Cancer Requires a Particularly Thoughtful Treatment Strategy
Pancreatic cancer remains one of the most challenging cancers in medicine.
The American Cancer Society estimates that approximately 67,530 people in the United States will be diagnosed with pancreatic cancer in 2026 and approximately 52,740 will die from the disease.2
One major reason is that pancreatic cancer can remain relatively silent while it is still small. The pancreas sits deep within the abdomen, and early tumors may not cause obvious symptoms.
By the time jaundice, significant weight loss, abdominal or back pain or digestive problems develop, the cancer may already be locally advanced or metastatic.
That makes the initial evaluation particularly important.
The first goal should not simply be “What treatment do we give?” It should be: “Exactly what cancer are we dealing with, how far has it spread, what biological information do we have about it, and what opportunities exist right now?”
Not Every Pancreatic Cancer Is the Same
The term “pancreatic cancer” encompasses more than one disease.
The majority of pancreatic cancers begin in the exocrine portion of the pancreas. The most common is pancreatic ductal adenocarcinoma, often abbreviated PDAC.
Pancreatic neuroendocrine tumors originate from different cells and can behave very differently. Their treatment, prognosis and molecular characteristics are not the same as pancreatic adenocarcinoma.
This page focuses primarily on pancreatic ductal adenocarcinoma, because that is the disease most people mean when they refer to pancreatic cancer.
Accurate pathology matters. Before planning treatment, it should be clear what type of tumor is actually present.
One of the Most Important Questions: Is the Cancer Resectable?
With pancreatic cancer, stage alone does not tell the entire story. Physicians also look closely at whether the tumor can be surgically removed. The National Cancer Institute identifies resectability as central to treatment planning.3
Resectable Pancreatic Cancer
The tumor appears technically removable with surgery and does not have major involvement of critical nearby blood vessels that would prevent an appropriate operation.
Borderline Resectable Pancreatic Cancer
The tumor has greater involvement with surrounding blood vessels, but surgery may still become possible depending on its exact anatomy and its response to treatment.
Locally Advanced Pancreatic Cancer
The tumor involves surrounding structures or major vessels in a way that prevents safe surgical removal at the time of evaluation, but there is no evidence of distant metastatic disease.
Metastatic Pancreatic Cancer
The cancer has spread beyond the pancreas to distant sites such as the liver, peritoneum, lungs or other organs.
A patient with a potentially resectable pancreatic tumor needs a fundamentally different strategy from a patient with widespread metastatic disease.
The Initial Pancreatic Cancer Evaluation Should Answer More Than One Question
A thorough review may involve:
- Pathology confirmation
- Pancreas-protocol CT imaging
- MRI when appropriate
- Endoscopic ultrasound
- Biopsy results
- Tumor location and size
- Relationship of the tumor to nearby arteries and veins
- Presence or absence of lymph-node involvement
- Evidence of liver, lung, peritoneal or other metastases
- CA 19-9 and other relevant laboratory results
- Liver and kidney function
- Blood counts
- Weight and recent weight loss
- Nutritional status
- Digestive symptoms
- Pain
- Current medications
- Previous chemotherapy, radiation or surgery
- Germline genetic testing
- Tumor molecular profiling when appropriate
- Performance status and physical function
The National Cancer Institute emphasizes that determining whether pancreatic cancer can be resected is a crucial part of appropriate treatment planning.3
That is why an imaging report saying “pancreatic mass” is only the beginning of the discussion.
Molecular and Genetic Testing Can Matter in Pancreatic Cancer
One of the biggest changes in modern pancreatic-cancer treatment is that physicians increasingly look beyond where the cancer started and examine what is driving the tumor biologically.
Genetic and molecular testing will not reveal a targetable abnormality in every patient. But when it does, the information can sometimes change treatment.
Germline Genetic Testing
Germline testing looks for inherited mutations that are present throughout the body.
Genes associated with hereditary pancreatic-cancer risk can include BRCA1, BRCA2, PALB2, ATM and genes involved in several hereditary cancer syndromes.
Importantly, clinically relevant germline alterations can occur even when a patient’s family history does not obviously suggest a hereditary syndrome. A prospective study of patients with exocrine pancreatic neoplasms supported broad germline testing because actionable inherited alterations were identified beyond traditional family-history criteria.4
Genetic information can have implications not only for the patient but potentially for family members.
Tumor Molecular Profiling
Tumor profiling looks for molecular changes within the cancer itself.
Most pancreatic cancers will not reveal an immediately targetable alteration, but a small subset can have findings that influence treatment or clinical-trial eligibility.
The value of testing is not that it guarantees a target. It is that potentially meaningful biology is less likely to be missed.
BRCA Mutations Can Influence Treatment
Patients with pancreatic cancer and certain DNA-repair abnormalities may respond differently to particular therapies.
One important example involves germline BRCA1 or BRCA2 mutations.
In the randomized phase III POLO trial, patients with metastatic germline BRCA-mutated pancreatic cancer whose disease had not progressed during platinum-based chemotherapy received maintenance treatment with the PARP inhibitor olaparib or placebo.
Median progression-free survival was significantly longer with olaparib—7.4 months versus 3.8 months in the original analysis.5
That does not mean olaparib is appropriate for every pancreatic-cancer patient. It demonstrates something much more important:
The molecular characteristics of a pancreatic tumor can sometimes create treatment opportunities that would be missed if every patient were treated as biologically identical.
Rare Molecular Findings Can Sometimes Create Additional Options
Some actionable abnormalities occur only in a small percentage of pancreatic cancers. But “rare” does not mean unimportant to the individual patient who has one.
In December 2024, the FDA granted accelerated approval to zenocutuzumab for adults with advanced unresectable or metastatic pancreatic adenocarcinoma containing an NRG1 gene fusion after progression following prior systemic treatment.6
It was the first FDA-approved systemic therapy specifically for pancreatic adenocarcinoma with that genetic alteration.
Other rare molecular findings may also have treatment implications in selected patients.
If adequate molecular and germline testing has not been performed, it may be worth asking why.
Conventional Pancreatic Cancer Treatment Has Also Advanced
A credible discussion of alternative pancreatic cancer treatment must accurately explain conventional treatment.
There are patients for whom surgery, chemotherapy, radiation or targeted treatment can provide meaningful benefit. Ignoring that evidence does patients a disservice.
The appropriate conventional strategy depends on whether disease is resectable, borderline resectable, locally advanced, recurrent or metastatic.
Surgery for Pancreatic Cancer
Surgery provides the primary opportunity for long-term disease control in appropriately selected patients with localized pancreatic adenocarcinoma.
Depending upon the location of the tumor, surgery may involve a pancreaticoduodenectomy, commonly known as the Whipple procedure, a distal pancreatectomy, or in selected circumstances a total pancreatectomy.
But pancreatic surgery should not be considered in isolation. Systemic therapy is an important part of modern treatment because even apparently localized pancreatic cancer can have microscopic disease outside the surgical field.
For some patients, chemotherapy is given before surgery. For others, systemic treatment follows surgery. The sequence depends upon resectability, tumor characteristics, the patient’s condition and multidisciplinary evaluation.
There Is Strong Evidence for Adjuvant Treatment After Surgery
One of the most important pancreatic-cancer trials was the PRODIGE 24 study.
Patients who had undergone surgical removal of pancreatic ductal adenocarcinoma were randomized to receive modified FOLFIRINOX or gemcitabine.
Long-term results showed a median overall survival of approximately 53.5 months with modified FOLFIRINOX versus 35.5 months with gemcitabine, and five-year overall survival was 43.2% versus 31.4%.7
Modified FOLFIRINOX is not appropriate for every postoperative patient, and it can produce significant toxicity.
But those results demonstrate why we should not frame conventional pancreatic-cancer therapy as something patients simply need to escape.
The goal of integrative care should be to understand where proven treatment has value and then determine what additional support may help the individual patient through that treatment.
Treatment Before Surgery May Be Important in Selected Patients
For patients with borderline resectable pancreatic cancer—and in carefully selected patients with potentially resectable disease—treatment may be given before an operation. This is called neoadjuvant treatment.
There are several reasons physicians consider this strategy:
- It begins treatment of potential microscopic disease sooner.
- It provides information about tumor biology.
- It may shrink or stabilize disease involving nearby vessels.
- It may increase the possibility of a margin-negative operation in selected situations.
- It helps identify cancers that progress rapidly and therefore may not benefit from a major operation.
Long-term results from the randomized PREOPANC study supported a survival benefit from a neoadjuvant chemoradiotherapy strategy in the population studied, although the optimal approach continues to evolve and differs between resectable and borderline-resectable disease.8
This is exactly the kind of situation in which pancreatic cancer benefits from multidisciplinary review rather than a one-size-fits-all answer.
Treatment for Metastatic Pancreatic Cancer
When pancreatic cancer has spread to distant organs, systemic therapy becomes the central conventional treatment.
Several multi-drug regimens are used depending upon the patient’s overall health, treatment history, tumor biology and ability to tolerate treatment.
One of the more important recent trials is NAPOLI 3.
In patients with previously untreated metastatic pancreatic ductal adenocarcinoma, NALIRIFOX was compared with gemcitabine plus nab-paclitaxel.
Median overall survival was approximately 11.1 months with NALIRIFOX compared with 9.2 months with gemcitabine plus nab-paclitaxel, and progression-free survival was also longer.9
These numbers are population averages. They cannot predict exactly what will happen to an individual patient.
But they demonstrate that treatment choices matter—and that pancreatic-cancer treatment continues to evolve.
Stage 4 Pancreatic Cancer Is Not the End of Medical Decision-Making
A diagnosis of Stage IV pancreatic cancer can make patients feel as though every meaningful option has disappeared.
Stage IV pancreatic cancer is serious and generally cannot be cured with current systemic therapy. But there may still be important decisions to make.
Questions worth asking include:
- Has the pathology been confirmed?
- Has adequate molecular profiling been performed?
- Has germline testing been completed?
- Is there a BRCA1, BRCA2, PALB2 or other potentially relevant DNA-repair abnormality?
- Is the tumor MSI-high or mismatch-repair deficient?
- Is there a rare actionable fusion such as NRG1 or NTRK?
- What systemic treatments have already been tried?
- Why was each treatment stopped?
- Was treatment stopped because it failed—or because the patient could not tolerate it?
- Could a modified dose or different regimen be considered?
- Are clinical trials available?
- How much of the patient’s current decline is caused by tumor burden versus dehydration, malnutrition, pancreatic enzyme insufficiency, pain, anemia or treatment toxicity?
Those are very different problems, and some are potentially addressable.
What If Pancreatic Cancer Treatment Has Stopped Working?
Reconfirm Where the Disease Is Now
Cancer biology changes over time. Current imaging may show a different pattern of disease than was present when treatment began.
Review Every Previous Treatment
For each regimen, ask what was given, at what dose, for how long, what the best response was, why it was stopped and what side effects occurred. Treatment stopped because of neuropathy is different from treatment stopped because of rapid tumor progression.
Review the Pathology and Molecular Data
Older biopsies may have been performed before current testing standards were applied. In some cases, additional molecular information may be useful.
Consider Clinical Trials
Because pancreatic cancer remains difficult to treat, the National Cancer Institute specifically encourages consideration of clinical trials across stages of the disease.3 Clinical trials are not only a “last resort.” They are how many of today’s standard treatments first became available.
Where Integrative Pancreatic Cancer Care Can Fit
Integrative care should not mean adding twenty treatments simply because a patient has pancreatic cancer.
Every intervention should have a purpose.
Potential goals may include:
- Supporting treatment tolerance
- Addressing nausea
- Addressing diarrhea or constipation
- Supporting hydration
- Managing fatigue
- Supporting nutritional status
- Preserving muscle mass and physical function
- Addressing sleep
- Helping manage anxiety and stress
- Addressing treatment-related symptoms
- Evaluating supplement and medication interactions
- Supporting recovery after surgery
- Identifying potentially correctable deficiencies
- Helping patients understand their treatment choices
- Coordinating care with conventional oncology when appropriate
- Preserving quality of life
This is an important distinction.
A treatment can be valuable because it helps a patient feel stronger, eat better, sleep better, remain hydrated or tolerate treatment more effectively without claiming that the intervention itself cures pancreatic cancer.
Good cancer care should be precise about the difference.
Pancreatic Cancer Can Affect Nutrition More Than Many Other Cancers
Nutrition deserves special attention in pancreatic cancer.
The pancreas produces enzymes needed to digest fats, proteins and carbohydrates. Pancreatic cancer—and pancreatic surgery—can interfere with this function.
Patients may experience reduced appetite, early fullness, nausea, diarrhea, pale or oily stools, abdominal bloating, difficulty digesting food, progressive weight loss, loss of muscle mass and weakness.
Some patients develop pancreatic exocrine insufficiency, meaning the pancreas is not producing or delivering enough digestive enzymes.
That should not simply be dismissed as “cancer weight loss.” It deserves evaluation.
For selected patients, pancreatic enzyme replacement, nutritional intervention and management of gastrointestinal symptoms can be important parts of supportive treatment.
Cancer-related cachexia can be particularly difficult in pancreatic cancer, and maintaining nutritional intake and lean body mass can become a significant clinical goal.
Weight Loss Is Not Always Something to Celebrate During Cancer Treatment
Patients often hear that weight loss and carbohydrate restriction are automatically beneficial because cancer cells use glucose.
Cancer metabolism is far more complicated than that.
A patient losing substantial muscle and body weight during pancreatic-cancer treatment may become weaker, tolerate therapy less effectively and lose functional independence.
There is no evidence that simply eliminating sugar “starves pancreatic cancer” while leaving the rest of the body unaffected.
Nutrition needs to be individualized.
For some patients, the priority is improving metabolic health. For another patient who has lost 25 pounds and struggles to eat, the priority may be getting adequate calories, protein and digestive support.
The nutritional strategy should fit the patient—not a slogan about cancer metabolism.
Pain and Symptom Control Are Part of Cancer Treatment
Pancreatic tumors can cause significant abdominal and back pain.
Pain may arise from tumor involvement around nerves and structures deep in the upper abdomen.
Appropriate management may include medication, radiation in selected circumstances, interventional pain procedures or procedures directed toward the celiac plexus.
Biliary obstruction can sometimes be relieved with endoscopic or radiologic stenting. Gastric outlet obstruction may also require intervention.
These treatments may not directly shrink every cancer cell, but they can dramatically affect how a patient feels and functions.
That matters.
Supportive and Palliative Care Does Not Mean Giving Up
The word “palliative” is frequently misunderstood.
Palliative care is not synonymous with hospice.
It means treating symptoms and protecting quality of life alongside cancer-directed care.
A randomized study of 207 patients with metastatic or locally advanced inoperable pancreatic cancer found that systematic early palliative care significantly improved quality-of-life measures compared with on-demand palliative care.10
A later prospective pancreatic-cancer study also found improvement in symptom burden among patients with metastatic disease receiving early palliative-care involvement.11
Treating the cancer and treating the person should happen at the same time.
Evidence-Informed Integrative Oncology Is Growing
Integrative oncology is becoming increasingly evidence-based.
ASCO and the Society for Integrative Oncology have developed evidence-based recommendations addressing areas such as anxiety and depression, cancer-related pain and cancer-related fatigue.121314
Depending upon the symptom and clinical circumstance, evidence-supported interventions can include exercise, mindfulness-based approaches, selected mind-body therapies, acupuncture for certain indications and other supportive interventions.
This does not mean every integrative therapy is proven. It means we should stop discussing integrative oncology as though everything within it has the same level of evidence.
Some interventions are well studied. Some have preliminary evidence. Some remain experimental. And some simply do not have convincing evidence.
Patients deserve to know the difference.
Alternative Pancreatic Cancer Treatment Should Not Mean Abandoning Treatments That May Help
There is a particularly important distinction for pancreatic cancer.
If a patient has a potentially resectable tumor, walking away from surgical evaluation in favor of an unproven alternative treatment could remove an important treatment opportunity.
If a patient’s tumor contains an actionable molecular alteration, failing to identify it could also remove an opportunity.
If systemic therapy is controlling disease, stopping it solely because a treatment is described as “natural” is not automatically safer.
Likewise, if conventional therapy is creating severe toxicity or has stopped working, there may be legitimate reasons to reassess the plan.
The right question is not “Conventional or alternative?” It is: “What combination of appropriate cancer-directed treatment, supportive care and evidence-informed integrative strategies makes sense for this patient now?”
What Makes the Sunridge Medical Approach Different?
At Sunridge Medical, we believe pancreatic-cancer care should involve more than a diagnosis followed by a standardized protocol.
The initial evaluation is designed to understand the complete clinical picture.
The Cancer
What exactly does the pathology show? Where is the primary tumor? Where has it spread? Is the disease potentially resectable?
The Biology
Has germline testing been performed? Has tumor profiling been performed when appropriate? Are there actionable findings?
Previous Treatment
What has already been tried? What worked? What did not? What could not be tolerated?
The Patient
What is happening with weight, nutrition, hydration, sleep, pain, digestive function, energy and physical function?
The Goal
Is the patient preparing for surgery? Receiving chemotherapy? Trying to tolerate treatment? Recovering after surgery? Facing recurrence? Searching for options after progression?
The answer changes the treatment strategy.
Why Patients Seek a Second Opinion at Sunridge Medical
A second opinion does not necessarily mean the original treatment plan was wrong.
Sometimes it confirms that the patient is already receiving the best available therapy. That reassurance itself can be valuable.
In other situations, another review may identify questions that have not yet been fully explored.
- Is the tumor truly unresectable?
- Has a pancreatic surgeon reviewed the imaging?
- Should treatment come before surgery?
- Has germline testing been completed?
- Has appropriate tumor profiling been performed?
- Are there clinical trials worth investigating?
- Are side effects being treated aggressively enough?
- Has significant weight loss been adequately addressed?
- Has pancreatic enzyme insufficiency been considered?
- Could supportive care improve treatment tolerance?
- Is the patient taking supplements that could interact with therapy?
The value of another opinion is not finding a reason to disagree. It is making sure important questions have not been overlooked.
You Do Not Have to Wait Until Everything Else Has Failed
Historically, many patients have approached alternative or integrative cancer clinics only after exhausting every conventional option.
We do see patients in that situation.
But integrative care can also begin much earlier.
A patient can seek another perspective:
- Immediately after diagnosis
- Before surgery
- During neoadjuvant treatment
- During chemotherapy
- After surgery
- During radiation
- During treatment breaks
- After recurrence
- After progression
- During Stage IV treatment
There can be an advantage to addressing nutrition, symptoms, medication interactions, functional status and supportive-care needs before the patient becomes severely depleted.
If You Are Coming to Sunridge Medical for Pancreatic Cancer, Bring the Entire Story
A useful pancreatic-cancer consultation depends upon having the right information. Whenever possible, bring or send:
- Pathology report
- Biopsy report
- Operative report
- CT reports
- MRI reports
- PET reports if performed
- Actual imaging files when available
- Endoscopic ultrasound report
- CA 19-9 history
- Recent CBC and chemistry results
- Liver-function tests
- Chemotherapy treatment history
- Radiation records
- Genomic or molecular testing
- Germline genetic-testing results
- Current medication list
- Current supplement list
- Recent weight history
- A timeline of diagnosis and treatment
The more complete the information, the more meaningful the discussion can be.
Questions Every Pancreatic Cancer Patient Should Be Asking
- What exact type of pancreatic cancer do I have?
- Is my cancer resectable, borderline resectable, locally advanced or metastatic?
- Has an experienced pancreatic surgeon reviewed my imaging?
- Should treatment occur before surgery?
- Has germline genetic testing been performed?
- Has molecular tumor profiling been performed if appropriate?
- What are my CA 19-9 trends telling us—and what can they not tell us?
- What is the goal of my current treatment?
- How will we know whether it is working?
- What is the next option if it stops working?
- Are there clinical trials that apply to my situation?
- What are we doing about weight loss and nutrition?
- Could I have pancreatic enzyme insufficiency?
- How are we addressing pain and digestive symptoms?
- Are any supplements I take capable of interacting with treatment?
- What can be done to help preserve my strength and quality of life?
Those are not “alternative medicine” questions. They are good cancer-care questions.
Why Patients Travel to Sunridge Medical in Scottsdale, Arizona
Patients come to Sunridge Medical because they want time to look more deeply at their case.
Many are not looking for someone to simply tell them to reject conventional care. They are looking for someone willing to ask: What else should we be considering?
They may want an individualized plan. They may want help supporting their body during treatment. They may want another review of a complicated history.
They may want to understand complementary options without being told that every natural substance cures cancer.
They may be trying to preserve strength and quality of life while undergoing aggressive treatment.
Or they may have been told that their disease has progressed and want someone to review whether meaningful options remain.
At Sunridge Medical, the conversation begins with the individual patient.
When Pancreatic Cancer Feels Overwhelming, Start With the Next Decision
Pancreatic cancer can make patients feel as though they have to understand the entire disease overnight.
You do not.
You need to understand the next important decision.
Is surgery possible? Does the pathology need review? Is systemic treatment needed? Has molecular testing been completed? Is a current therapy working? Is toxicity becoming unacceptable? Is weight loss becoming dangerous? Is pain controlled? Are there clinical trials? Is there another legitimate treatment option?
Those questions are manageable one at a time.
Hope does not require pretending that pancreatic cancer is easy to treat. Hope means continuing to look carefully at the evidence, the patient and the options that are actually available.
Speak With the Sunridge Medical Patient Care Team
If you or someone you love has been diagnosed with pancreatic cancer, you do not have to navigate every treatment question alone.
Whether you are newly diagnosed, currently undergoing treatment, considering surgery, facing recurrent or metastatic disease, or looking for another perspective after previous treatments have stopped working, Sunridge Medical can review your situation and help you understand the next steps.
Sunridge Medical • Scottsdale, Arizona
FREQUENTLY ASKED QUESTIONS
Frequently Asked Questions About Alternative Pancreatic Cancer Treatment
Can pancreatic cancer be treated naturally?
No natural treatment has been established as a universal replacement for medically indicated pancreatic-cancer surgery, chemotherapy, targeted therapy or radiation. Integrative therapies may have roles in supportive care, symptom management and quality of life, but evidence varies considerably by intervention. Patients should be particularly cautious about abandoning potentially curative surgery for an unproven treatment.
What is the best alternative pancreatic cancer treatment?
There is no single alternative pancreatic cancer treatment that has been proven to work for every patient. The appropriate strategy depends upon the exact type of pancreatic cancer, whether it can be surgically removed, disease stage, molecular findings, previous treatment, overall health and treatment goals. A useful integrative plan should be individualized rather than based on a universal protocol.
Can Stage 4 pancreatic cancer be treated?
Stage IV pancreatic cancer is treatable, although it is generally not considered curable with currently available systemic therapies. Chemotherapy, selected targeted therapies, clinical trials, symptom-directed treatment and supportive care may all play a role depending upon the patient. Molecular and genetic testing can be particularly important because a small subset of patients have findings that influence treatment.
Should pancreatic-cancer patients have genetic testing?
Genetic testing has become increasingly important in pancreatic adenocarcinoma. Inherited abnormalities involving genes such as BRCA1, BRCA2 and PALB2 can have treatment and family implications. Tumor molecular profiling may also identify uncommon but potentially actionable abnormalities in selected patients.
Can someone receive integrative care while undergoing chemotherapy?
Yes. Integrative care can be used alongside conventional oncology when therapies are selected carefully and potential interactions are reviewed. The goal may be to support nutrition, hydration, physical function, symptom management, sleep, stress and treatment tolerance. Any supplement or complementary intervention should be considered in the context of the patient’s exact chemotherapy regimen and medications.
What if chemotherapy has stopped working?
Progression should prompt reassessment. That may include updated imaging, review of previous regimens, pathology review, molecular testing, germline testing, consideration of a different systemic regimen, targeted therapy when appropriate and clinical-trial evaluation. Treatment options depend heavily upon what has already been used and the patient’s condition.
Is pancreatic cancer always Stage 4 when it is diagnosed?
No. Pancreatic cancer can be diagnosed at localized, locally advanced or metastatic stages. However, early pancreatic cancer frequently causes few symptoms, which is why many cases are diagnosed after the disease has become advanced.
Is surgery possible for Stage 4 pancreatic cancer?
Surgery to remove the primary pancreatic tumor is generally not a standard curative strategy when widespread distant metastatic disease is present. The situation is different for localized or selected borderline-resectable disease, where surgical evaluation can be extremely important.
Does sugar feed pancreatic cancer?
Cancer cells use glucose, but the idea that eliminating dietary sugar can selectively starve pancreatic cancer is an oversimplification of cancer metabolism. Patients with pancreatic cancer are particularly vulnerable to weight loss and muscle wasting. Nutrition should therefore be individualized to the patient’s metabolic health, digestive function, weight and treatment status.
Why is molecular testing important in pancreatic cancer?
Most pancreatic cancers will not have an easily targetable alteration. However, some patients have inherited or tumor-specific changes that can affect treatment. Examples include BRCA-related DNA-repair abnormalities and rare NRG1 fusions. The information can also identify potential clinical-trial opportunities.
When should I seek a second opinion?
A second opinion can be valuable immediately after diagnosis, before a major operation, when a tumor is described as unresectable, before starting a new systemic treatment, after cancer progression, or whenever important questions remain unanswered. You do not have to wait until every treatment has failed.
SOURCES
References
- National Cancer Institute. Complementary and Alternative Medicine (CAM). Definitions of complementary, alternative and integrative medicine.
- American Cancer Society. Facts About Pancreatic Cancer. 2026 U.S. incidence and mortality estimates.
- National Cancer Institute. Pancreatic Cancer Treatment (PDQ®) – Health Professional Version. Evidence-based overview of resectability, treatment and clinical trials.
- Lowery MA, Wong W, Jordan EJ, et al. Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal of the National Cancer Institute. 2018;110(10):1067-1074.
- Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. New England Journal of Medicine. 2019;381:317-327. doi:10.1056/NEJMoa1903387.
- U.S. Food and Drug Administration. FDA Grants Accelerated Approval to Zenocutuzumab-zbco for NRG1 Fusion-Positive Pancreatic Adenocarcinoma. December 4, 2024.
- Conroy T, Castan F, Lopez A, et al. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. JAMA Oncology. 2022;8(11):1571-1578.
- Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. Journal of Clinical Oncology. 2022;40(11):1220-1230.
- Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX Versus Nab-Paclitaxel and Gemcitabine in Treatment-Naive Patients With Metastatic Pancreatic Ductal Adenocarcinoma (NAPOLI 3). The Lancet. 2023;402(10409):1272-1281.
- Maltoni M, Scarpi E, Dall’Agata M, et al. Systematic Versus On-Demand Early Palliative Care: Results From a Multicentre, Randomised Clinical Trial. European Journal of Cancer. 2016;65:61-68.
- Kim CA, Lelond S, Daeninck PJ, et al. The Impact of Early Palliative Care on the Quality of Life of Patients With Advanced Pancreatic Cancer: The IMPERATIVE Case-Crossover Study. Supportive Care in Cancer. 2023;31(4):250.
- Carlson LE, Ismaila N, Addington EL, et al. Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology–ASCO Guideline. Journal of Clinical Oncology. 2023;41(28):4562-4591.
- Mao JJ, Ismaila N, Bao T, et al. Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology–ASCO Guideline. Journal of Clinical Oncology. 2022;40(34):3998-4024.
- Bower JE, Lacchetti C, Alici Y, et al. Management of Fatigue in Adult Survivors of Cancer: ASCO–Society for Integrative Oncology Guideline Update. Journal of Clinical Oncology. 2024.
